Test your knowledge on treatment and management of mTNBC

Which of the following adverse events is the most common endocrinopathy following treatment with anti-PD-L1 monotherapy?
Graves' disease
Adrenal insufficiency
Hypothyroidism
Diabetes mellitus
Sacituzumab govitecan received approval in the USA for treating patients with mTNBC following at least 2 prior therapies in the metastatic setting.
True
False
How is cardiotoxicity defined?
Decline in LVEF of 10% to a final value of under 40%
Decline in LVEF of 15% to a final value of under 33%
Decline in LVEF of at least 10% to a final value of under 50%
Decline in LVEF of 15% to a final value of under 53%
Which of the following therapies would you administer prior to infusion with sacituzumab govitecan?
Single-agent antiemetic, antibiotic, antipyretic
Antibiotic, antiemetic, H2 blocker
Antiemetic, H2 blocker, steroid
Combination antiemetics, antipyretic, H2 blocker
Which of the following regimens are recommended as a second-line therapy for patients with a known germline BRCA mutation and no PD-L1 expression?
Single-agent chemotherapy
Single-agent chemotherapy and olaparib
Pembrolizumab
Olaparib
Of the following, who is at the greatest risk of developing TNBC?
Postmenopausal Latin women
Postmenopausal Caucasian women
Premenopausal Native American women
Premenopausal African American women
In the KEYNOTE-355 study, which of the following agents demonstrated a relative 27% decrease in the risk of death vs chemotherapy alone for patients with mTNBC whose tumors were strongly positive for PD-L1?
Atezolizumab and chemotherapy
Sacituzumab govitecan
Pembrolizumab and chemotherapy
Pembrolizumab alone
Approximately how many patients with mTNBC develop brain metastases?
1/12
1/5
1/3
None of these
Which of the following adverse events is associated with olaparib? (Choose all that apply)
Nephritis with renal dysfunction
Myelodysplastic syndrome
Disseminated intravascular coagulation
Which trial showed that trastuzumab deruxtecan improved progression-free survival and overall survival in patients with HER2-low metastatic breast cancer?
CAPItello-292
SERENA-1
DESTINY-Breast04
CERTIS1
{"name":"Test your knowledge on treatment and management of mTNBC", "url":"https://www.poll-maker.com/QE9RRUPZO","txt":"Which of the following adverse events is the most common endocrinopathy following treatment with anti-PD-L1 monotherapy?, Sacituzumab govitecan received approval in the USA for treating patients with mTNBC following at least 2 prior therapies in the metastatic setting., How is cardiotoxicity defined?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys